PYXS 3.75 (+16.1%)
US7473241013BiotechnologyBiotechnology

Pyxis Oncology (PYXS) Stock Highlights

3.75 | +16.1%
2024-10-21 04:31:14
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Statistics

Range Today
3.23 3.79
Volume Today 1.67M
Range 1 Year
1.35 6.85
Volume 1 Year 132.03M
Range 3 Year
1.1 14
Volume 3 Year 445.72M
Range 10 Year
1.1 19
Volume 10 Year 452.91M

Highlights

Market Capitalization 222.84M (small)
Floating Shares 38.74M
Current Price 3.75
Price To Earnings -2.57
Price To Revenue 5.34
Price To Book 1.3
Earnings Per Share -1.27
Payout Ratio 0%

Performance

Latest +16.1%
1 Month +3.59%
3 Months +15.38%
6 Months -22.84%
1 Year +106.04%
3 Years -68.75%
5 Years -80.26%
10 Years -80.26%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.